SecBot SecBot
6-K ·Filed Aug 17, 2026

AZN

ASTRAZENECA PLC
BULLISH
Impact 7/10
Horizonmonths Processed3mo ago SEC0001654954-26-007677
Notable filing: 6-K
Actionable Insight ▲ Bullish

SAFFRON data de-risks global regulatory filings for Tagrisso+Orpathys in MET-driven post-Tagrisso EGFRm NSCLC, a high-unmet-need population. Watch for regulatory submissions in US/EU over next 6-12 months and potential peak sales contribution. The combination strengthens AstraZeneca's lung cancer franchise against competitive threats.

DirectionBullish
Confidencehigh
Horizonmonths

Drugs in focus

AZN drug pipeline →

ORPATHYS

◆ Mixed Named in this 6-K
Impact
Phase
Approved in China (3 indications); global Phase 3 readout pending
Time to market
Already approved and marketed in China (lung cancer since 2021, gastric cancer July 2026). Ex-China (US/EU) approval is not filed yet — timing hinges on the SAFFRON global Phase 3 readout expected H2 2026.
Next catalyst
None dated

What to watchWatch for SAFFRON/SANOVO Phase 3 topline data in H2 2026, a positive readout supports global (ex-China) filings for savolitinib and would be the biggest near-term share-price lever; a miss or delay would hit a stock already near its 52-week low ($11.13 vs $18.30 high). HUTCHMED carries $1.37B cash, so the stock isn't a financing story, but this one drug's readout is the dominant H2 catalyst alongside sovleplenib NDA decisions.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$156.89
T+0 close · Aug 17, 2026 · via day close
Latest settled
+20.72%
T+60 · $189.39
Vs SPY
+23.48%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 17 $156.89entry
  2. T+1 · 3mo ago +2.05%α +2.72% · $160.10
  3. T+5 · 3mo ago +6.26%α +7.45% · $166.71
  4. T+20 · 2mo ago +4.39%α +5.92% · $163.78
  5. T+60 · 7d ago +20.72%α +23.48% · $189.39
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AstraZeneca announced positive Phase III SAFFRON trial results showing Tagrisso plus Orpathys significantly improved progression-free survival (PFS) and overall survival (OS) vs chemotherapy in EGFR-mutated NSCLC patients with MET-driven resistance after Tagrisso progression. This is the first global Phase III to show both PFS and OS benefit in this setting, supporting global regulatory submissions and reinforcing Tagrisso's backbone role in EGFRm lung cancer.

Key Facts

  • SAFFRON Phase III trial met dual primary endpoint of PFS and key secondary endpoint of OS with statistical significance and clinical meaningfulness vs doublet platinum-based chemotherapy.
  • Trial enrolled 338 patients across 230 centers in 29 countries; patients had EGFRm NSCLC with high MET overexpression/amplification after progression on Tagrisso.
  • Safety profile consistent with known profiles of each medicine; no new safety findings.
  • Data to be presented at forthcoming medical meeting and shared with global regulatory authorities.
  • Tagrisso plus Orpathys already approved in China for this indication based on SACHI Phase III; temporary authorization granted in Switzerland based on SAVANNAH Phase II.
  • Orpathys is jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.

Financial Impact

Positive read-through for Tagrisso franchise (AstraZeneca's top-selling drug) and Orpathys; potential to address ~34% of Tagrisso progressors who develop MET-driven resistance; supports global label expansion and revenue upside.

revenuepipeline value

Risk Factors

  • Regulatory timelines and approval decisions outside China are uncertain.
  • Competing MET-targeted therapies (e.g., amivantamab combinations) could limit market share.
  • Pricing and reimbursement dynamics for combination therapy may affect adoption.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (35 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-007677
Document: 0001654954-26-007677-index-headers.html0001654954-26-007677
Document: 0001654954-26-007677-index.html0001654954-26-007677
Document: 0001654954-26-007677.txt0001654954-26-007677

Track record

77 reports on AZN

Performance horizon

18 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 28 of 37 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
  2. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.45 −0.59% settles Nov 23
  3. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.45 −0.46% settles Nov 23
  4. Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.45 −0.35% settles Nov 23
  5. Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.45 −1.28% ▼ −1.32% −4.61% vs SPY
  6. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.45 −1.14% ▲ +1.51% +1.43% vs SPY
  7. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.45 −1.14% ▲ +1.51% +1.43% vs SPY
  8. Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.45 −1.18% ▼ −0.12% +2.59% vs SPY
  9. Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.45 +8.45% ▲ +8.11% +10.10% vs SPY
  10. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.45 +6.88% ▲ +0.51% −0.19% vs SPY
Showing 10 of 77

US Market Status

Market Closed · Opens Wed (13h 30m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 17, 2026